CardioVascular BioTherapeutics, Inc. (CVBT.OB) is a biopharmaceutical company focused on developing protein drug candidates to be used in the treatment of cardiovascular disease. Cardiovascular disease is the worldwide leading cause of death.
The Company is developing injectable and topical formulations of their already active pharmacological ingredient (API) in order to facilitate the growth of new blood vessels (angiogenesis) in the heart, tissues and organs that have been compromised by impaired blood supply (hypoxia, ischemia). The Company’s API contains FGF-1141; a human protein manufactured using a proprietary technology. FGF-1 stimulates the growth and proliferation of the three main cell types of blood vessels; endothelial cells, smooth muscles cells and pericytes.
The Company’s lead drug candidate successfully completed initial clinical trials in Germany during the 1990s, with no drug-related adverse events and a statistically significant increase in localized blood vessel growth (and perfusion). Enrollment and treatment has been completed in an FDA authorized Phase I study with CVBT-141A, administered via injection in severe CHD patients.
CardioVascular BioTherapeutics, Inc. is committed to conducting additional clinical trials to establish the positive effect of FGF-1141 aimed at improving the quality of life for those suffering from heart disease, stroke, diabetic wounds, or peripheral artery disease, and pledges to continue exploration for additional applications of FGF-1.
Let us hear your thoughts: CardioVascular BioTherapeutics, Inc. Message Board